Tag - SWTX

SpringWorks Therapeutics (NASDAQ:SWTX) dosed the first patient in its Phase 2b trial evaluating mirdametinib in children and adults with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PN).  NF1 is a...